For Rare Disease Day, our founder Emily Crossley, and Alex Johnson of Joining Jack, are going to the offices of Summit PLC to speak to the company and families about the importance of the patient voice in drug development. 

We'd also like to welcome a new member to our Scientific Advisory Board, Bob MdcDonald.

Bob is the father of 9 children, including his very special youngest son, Mark, age 11, diagnosed with DMD at age 2.  He is a practicing ENT surgeon in the US and is the immediate past chairman of Parent Project Muscular Dystrophy (PPMD). He currently serves on the scientific advisory board of PPMD and is a reviewer for the US Department of Defence DMD Research Programme.

He is also a member of the TREAT-NMD Advisory Committee on Therapeutics (TACT) where he has performed numerous reviews.

Along with everyone on the scientific advisory board and at the DCT, Bob is determined to End Duchenne in Ten.

We are delighted to welcome him on board.